AKT1 and non-small cell lung carcinoma: A previous study has demonstrated that EZH2 can promote H3K27me3 modification of PTEN promoter region, which inhibits PTEN expression and activates PI3K/AKT pathway to promote the proliferation and metastasis of NSCLC cells.16